Evidence map›Paper›PMID 40222820›Full record

Trial reportEuropean journal of heart failure2025

Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial.

Jawad H Butt, Pardeep S Jhund, Alasdair D Henderson, Brian L Claggett, Akshay S Desai, Carolyn S P Lam, Katharina Mueller, Markus F Scheerer, Prabhakar Viswanathan, Michele Senni and 7 more

Registry-linked trialAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04435626 (A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Finerenone on Morbidity and Mortality in Participants With Heart Failure), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04435626 phase3completednot on this map

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Finerenone on Morbidity and Mortality in Participants With Heart Failure (NYHA II-IV) and Left Ventricular Ejection Fraction ≥ 40% (LVEF ≥ 40%)

TypeinterventionalSponsorBayerRan2020 to 2024Enrolled6,016ConditionsHeart FailureArmsFinerenone (BAY94-8862), Placebo
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jawad H ButtBritish Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Pardeep S JhundBritish Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Alasdair D HendersonBritish Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Brian L ClaggettCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Akshay S DesaiCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Carolyn S P LamNational Heart Centre Singapore & Duke-National University of Singapore, Singapore, Singapore.
Katharina MuellerBayer, Research & Development, Pharmaceuticals, Wuppertal, Germany.
Markus F ScheererBayer, Global Medical Affairs, Berlin, Germany.
Prabhakar ViswanathanBayer, Research & Development, Pharmaceuticals, Whippany, NJ, USA.
Michele SenniUniversity of Milano-Bicocca, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy.
Sanjiv J ShahNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.
Adriaan A VoorsUniversity of Groningen, Groningen, The Netherlands.
Faiez ZannadUniversity of Lorraine, Nancy, France.
Bertram PittUniversity of Michigan, Ann Arbor, MI, USA.
Muthiah VaduganathanCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Scott D SolomonCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
John J V McMurrayBritish Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsChronic obstructive pulmonary disease (COPD) is associated with worse outcomes in heart failure (HF) with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). A post hoc analysis of TOPCAT suggested that the effectiveness of the steroidal mineralocorticoid receptor antagonist (MRA), spironolactone, may be modified by pulmonary disease, with a greater benefit in patients with COPD/asthma. We examined the effects of the non-steroidal MRA, finerenone, compared to placebo, according to COPD status in a prespecified analysis of FINEARTS-HF. METHODS AND

resultsA history of COPD was investigator-reported. The primary outcome was the composite of cardiovascular death and total worsening HF events. Of the 6001 patients randomized in FINEARTS-HF, 773 patients (12.9%) had COPD. Compared to patients without COPD, those with COPD had more adverse clinical features, including worse New York Heart Association class and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, more prior HF hospitalization, atrial fibrillation/flutter, obesity, peripheral artery disease, and hypertension, as well as elevated high-sensitivity troponin T levels. Patients with COPD had a higher risk of the primary endpoint (adjusted rate ratio [RR] 1.44, 95% confidence interval [CI] 1.21-1.71). The benefit of finerenone on the primary outcome was consistent irrespective of COPD status (no COPD: RR 0.84 [95% CI 0.73-0.97]; COPD: 0.84 [95% CI 0.61-1.16]; p

conclusionIn patients with HFmrEF/HFpEF, the beneficial effects of finerenone on clinical events and symptoms were consistent, regardless of COPD status. CLINICAL

trial registrationClinicalTrials.gov ID NCT04435626.

Indexed as

Heart FailureNaphthyridinesPulmonary Disease, Chronic ObstructiveStroke VolumeAgedDouble-Blind MethodFemaleHumansMaleMiddle AgedMineralocorticoid Receptor AntagonistsTreatment OutcomefinerenoneMineralocorticoid Receptor AntagonistsNaphthyridinesChronic obstructive pulmonary diseaseHeart failure with preserved ejection fractionMineralocorticoid receptor antagonist

Identifiers

PMID40222820
PMCPMC12482838

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.